New hope for hard-to-treat bladder cancer: experimental drug combo enters human trials
NCT ID NCT05562830
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called zilovertamab vedotin, alone or with the immunotherapy pembrolizumab, in 48 people with advanced bladder cancer that no longer responds to standard PD-1/L1 inhibitors. The study aims to see if the treatment is safe and can shrink tumors. It is part of a larger platform trial that can add new treatments as they become available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zilovertamab vedotin (a drug that targets cancer cells) with or without pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with advanced bladder cancer that no longer responds to standard immunotherapy.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anschutz Cancer Pavilion ( Site 1017)
COMPLETEDAurora, Colorado, 80045, United States
-
Asan Medical Center ( Site 1901)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
Bradford Hill ( Site 1155)
RECRUITINGSantiago, Region M. de Santiago, 8420383, Chile
Contact Phone: •••-•••-••••
-
Cleveland Clinic-Taussig Cancer Center ( Site 1036)
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-••••
-
FALP-UIDO ( Site 1151)
RECRUITINGSantiago, Region M. de Santiago, 7500921, Chile
Contact Phone: •••-•••-••••
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1408)
RECRUITINGMilan, Lombardy, 20133, Italy
Contact Phone: •••-•••-••••
-
Hospital Clinico San Carlos ( Site 1765)
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall d'Hebron ( Site 1767)
RECRUITINGBarcelona, Catalonia, 08035, Spain
Contact Phone: •••-•••-••••
-
Huntsman Cancer Institute ( Site 1041)
RECRUITINGSalt Lake City, Utah, 84112-5500, United States
Contact Phone: •••-•••-••••
-
Indiana University Melvin and Bren Simon Cancer Center ( Site 1011)
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-••••
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406)
RECRUITINGNaples, 80131, Italy
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center ( Site 1031)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1302)
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact Phone: •••-•••-••••
-
Princess Margaret Cancer Centre ( Site 1106)
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1201)
RECRUITINGLondon, London, City of, SW3 6JJ, United Kingdom
Contact Phone: •••-•••-••••
-
Rabin Medical Center-Oncology ( Site 1504)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus-Oncology ( Site 1501)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Rigshospitalet-Dept. of Oncology ( Site 1701)
RECRUITINGCopenhagen, Capital Region, 2100, Denmark
Contact Phone: •••-•••-••••
-
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952)
COMPLETEDBrisbane, Queensland, 4029, Australia
-
Samsung Medical Center ( Site 1902)
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 1903)
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Sheba Medical Center-ONCOLOGY ( Site 1503)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
Siteman Cancer Center ( Site 1038)
RECRUITINGSt Louis, Missouri, 63108, United States
Contact Phone: •••-•••-••••
-
St Bartholomew's Hospital ( Site 1206)
RECRUITINGLondon, London, City of, EC1A 7BE, United Kingdom
Contact Phone: •••-•••-••••
-
UPMC Hillman Cancer Center ( Site 1014)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-••••
-
University of California San Francisco ( Site 1044)
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-••••
-
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-••••
-
University of Chicago Medical Center ( Site 1037)
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-••••